Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B

Program in Québec's Saguenay-Lac-Saint-Jean region is the first public campaign globally to offer Bexsero to all from 2 months to 20 years of age[1] More than 45,000 infants, young children and...
July 28, 2014 01:15 ET | Source: Novartis Pharma AG

Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease

Simbrinza provides a convenient option to reduce treatment burden versus concomitant administration of single drugs Simbrinza is the only beta blocker-free formulation combining two approved...
July 24, 2014 01:15 ET | Source: Novartis Pharma AG

FDA accepts Sandoz application for biosimilar filgrastim

Sandoz is the first company to announce it has filed for approval of a biologic under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA). FDA's...
July 17, 2014 01:00 ET | Source: Novartis Pharma AG

Novartis a maintenu, au deuxième trimestre, le rythme accéléré de l'innovation, reconfirmant ainsi les perspectives de l'exercice complet

Hausse de 2%[1] du chiffre d'affaires net au deuxième trimestre (T2), avec un levier opérationnel core au T2 et au premier semestre (S1) Chiffre d'affaires net d'USD 14,6 milliards en augmentation...
July 17, 2014 01:00 ET | Source: Novartis Pharma AG

Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook

Net sales grew 2%[1] in Q2, with core operating leverage across Q2 and H1 Net sales of USD 14.6 billion grew 2% (+2% cc[2]) in Q2; USD 28.7 billion (+2%, +2% cc) in H1 Strong operating income growth...
July 17, 2014 01:00 ET | Source: Novartis Pharma AG

Novartis setzt im zweiten Quartal die starke Dynamik im Innovationsbereich fort und bekräftigt erneut den Ausblick für das Gesamtjahr

Der Nettoumsatz wächst im zweiten Quartal um 2%[1] - bei einem operativen Hebeleffekt auf die Kernergebnisse in beiden Berichtszeiträumen Der Nettoumsatz steigt im zweiten Quartal um 2% (+2%...
July 15, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis to license Google "smart lens" technology

Innovative technology offers potential to transform eye care and further enhance Alcon's leadership in contact lenses and intraocular lenses Agreement is a first step for Novartis to evolve...
July 15, 2014 00:00 ET | Source: Novartis Pharma AG

Novartis announces collaboration with Banner Alzheimer's Institute on a pioneering prevention study for Alzheimer's Disease

Two Novartis anti-amyloid investigational treatments will be studied in people with a genetic risk of developing Alzheimer's Disease (AD) The build-up of amyloid in the brain is believed to be a...
July 09, 2014 17:00 ET | Source: Novartis Pharma AG

Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of secukinumab (AIN457) in psoriasis patients

Results of two phase III psoriasis studies consistently show rapid, very high skin clearance, sustained efficacy and an acceptable safety profile with secukinumab[1] More than 70% of secukinumab...
July 09, 2014 01:15 ET | Source: Novartis Pharma AG

Novartis releases 2013 Corporate Responsibility Performance Report using best-in-class reporting standard, increasing transparency

2013 Corporate Responsibility (CR) Performance Report builds on a long history of CR and reporting Report uses new Global Reporting Initiative G4 guidelines, one year ahead of required...